Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

ially and/or adversely affect actual future results and the market price of the Company's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory aggressive NHL and/or other tumors as determined by the FDA and/or the EMA, that the FDA may not accept the Company's proposed design for the protocol of the Company's PIX306 clinical trial and/or may request additional clinical trials, that if the Company conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that the Company cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that the Company cannot guarantee when it will initiate a new clinical trial for pixantrone, that the FDA may not approve the Company's special protocol assessment, that the Company cannot predict the outcome of its appeal to the FDA, that the Company's appeal may not be successful, that the EMA may not approve the Company's MAA after review, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, the Company does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.Media Contact:Dan Eramian T: 206.272.4343C: 206.854.1200E: deramian@ctiseat
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... -- The discovery 30 years ago of soccer-ball-shaped carbon ... nanotechnology research. Now, there appears to be a new ... Shanxi University and Tsinghua University in China have shown ... hollow molecular cage similar to a carbon buckyball. It,s ... only a matter of speculationdoes indeed exist. , "This ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... analysis for various reagents used in the ... is driving the life science reagents market ... study include manufacturers and providers of life ... Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , ...
(Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... blood, termed ,endometrial regenerative cells, (ERCs) are capable ... of advanced peripheral artery disease. A study published ... Translational Medicine demonstrates that when circulation-blocked mice were ... restored. , Critical limb ischemia, an ...
... SAN JOSE, Calif., Aug. 18 VNUS(R) Medical,Technologies, ... quarter results and,revises its full year 2008 guidance. ... operating expenses and certain balance sheet accounts,to record ... appropriately recorded in prior periods since the adoption ...
... (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company,focused on ... ended June 30, 2008., Net loss was $3.8 ... June 30, 2008, compared to $0.5 million, or $0.05 ... was $7.5 million, or $0.65 per share, for the,six ...
Cached Biology Technology:Limbs saved by menstrual blood stem cells 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 3VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 4Arno Therapeutics Announces Second Quarter 2008 Financial Results 2Arno Therapeutics Announces Second Quarter 2008 Financial Results 3Arno Therapeutics Announces Second Quarter 2008 Financial Results 4Arno Therapeutics Announces Second Quarter 2008 Financial Results 5
(Date:7/14/2014)... to the discovery and description of Rhipidocyrtus muiri ... turned out to represent a new genus and species. The ... from Borneo is discussed in a recent paper published in ... The holotype male, and only known specimen of Rhipidocyrtus ... subsequent to this it was transferred among several researchers in ...
(Date:7/14/2014)... consequence of aging? , Although it is widely thought ... risk of developing several common cancers decreases with age. ... decrease with age in the risk of developing certain ... puzzle was presented in a recent paper published in ... P. Brody of the Department of Biomedical Engineering at ...
(Date:7/13/2014)... A new study in women suggests that experiencing one ... single high-fat meal can slow the body,s metabolism, potentially ... about the previous day,s stressors before giving them a ... fat. The scientists then measured their metabolic rate ... and fat and took measures of blood sugar, ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... dengue fever will be the early targets of new ... The University of Queensland (UQ) and the University ... after Queensland Premier Anna Bligh announced $650,000 from the ... "Detection of the pathogens of two debilitating ...
... SAN DIEGO, CA (June 18, 2008): Despite recent controversies ... opportunities to create a more sustainable world, with applications ... for industrial and consumer uses, and high quality agricultural ... and technologies to be truly sustainable, they must be ...
... Earth,s periodic mass extinction events such as the sudden demise ... crashing asteroids and sky-darkening super volcanoes as culprits. But ... Nature , suggests that it is the ocean, and ... and sediment over the course of geologic time, that is ...
Cached Biology News:Biotechnology key to developing sustainable industries says international panel 2Biotechnology key to developing sustainable industries says international panel 3The mystery of mass extinctions is no longer murky 2The mystery of mass extinctions is no longer murky 3
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
... BalanceTalk XL provides balance data collection and ... Complete integration with Microsoft Excel , ... moisture analyzers , New balances can be added ... Collect data from multiple balances into one spreadsheet ...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Biology Products: